Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.45 |
| ▸ | TPH1 | P17752 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | FCER2 | P06734 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268864 | 1.00 | AKT1 (0.45) | AKT1TPH1CYP1A2PDGFRBPDGFRA | |
| SCHEMBL1163847 | 0.82 | PDGFRB (0.44) | AKT1TPH1CYP1A2PDGFRBPDGFRA | |
| SCHEMBL27833024 | 0.81 | AKT1 (0.43) | AKT1TPH1CYP1A2PDGFRBPDGFRA | |
| SCHEMBL23009533 | 0.80 | HTR2A (0.57) | AKT1CYP1A2PDGFRBPDGFRAMMP1 | |
| SCHEMBL22401385 | 0.80 | HTR2A (0.57) | AKT1CYP1A2PDGFRBPDGFRAMMP1 | |
| SCHEMBL529903 | 0.80 | CYP1A2 (0.44) | CYP1A2PDGFRBPDGFRARAB9AKMT2A | |
| SCHEMBL2267928 | 0.79 | CYP1A2 (0.44) | AKT1TPH1CYP1A2PDGFRBPDGFRA | |
| SCHEMBL2267925 | 0.79 | CYP1A2 (0.44) | AKT1TPH1CYP1A2PDGFRBPDGFRA | |
| SCHEMBL287073 | 0.78 | TPH1 (0.62) | TPH1RAB9AMMP1FCER2MMP3 | |
| SCHEMBL30969128 | 0.78 | TPH1 (0.62) | TPH1RAB9AMMP1FCER2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| JP-H09501913-A | — | — | 1997-02-25 | — | — | JP | claimed |
| EP-0738154-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | Abbott Laboratories (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0738154-A4 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LAB (US) | 1996-04-12 | — | — | EP | claimed |
| US-5502035-A | N-terminus modified analogs of LHRH | TAP HOLDINGS INC. (US) | 1996-03-26 | — | — | US | claimed |
| WO-1995004541-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LABORATORIES (US) | 1995-02-16 | — | — | WO | claimed |
| WO-1995004540-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LABORATORIES (US) | 1995-02-16 | — | — | WO | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | disclosed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | disclosed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | disclosed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | AKT1 3810/4885TPH1 1129/4885CYP1A2 3674/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | AKT1 3810/4885TPH1 1129/4885CYP1A2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.